Skip to main content
. 2020 Jun;6(2):101–110. doi: 10.18383/j.tom.2020.00009

Figure 1.

Figure 1.

I‐SPY 2 study schema and adaptive randomization. Patients were randomized to the control (paclitaxel for HER2− or paclitaxel + trastuzumab for HER2+) or one of the experimental drug arms. Participants received a weekly dose of paclitaxel alone (control) or in combination with an experimental agent for 12 weekly cycles followed by 4 (every 2–3 weeks) cycles of anthracycline–cyclophosphamide (AC) before surgery.